People with type 2 diabetes (T2D) who take semaglutide — an active ingredient in popular diabetes and weight-loss drugs such as Ozempic and Wegovy — have a markedly lower risk of developing Alzheimer’s disease, according to an article published Thursday in Alzheimer’s & Dementia magazine.
A group of scientists at Case Western Reserve University School of Medicine in Cleveland analyzed three years of electronic records from nearly a million American patients with T2D using a statistical approach that mimics a randomized clinical trial.
“This new study provides real-world evidence of its impact on Alzheimer’s disease, although preclinical research has suggested that semaglutide may protect against neurodegeneration and neuroinflammation,” explained Rong Xu, professor of biomedical informatics and co-author of the study.
Likewise, he pointed out that the results indicate that they will have to continue investigating the use of semaglutide through randomized clinical trials to be able to test alternative drugs as a potential treatment for this brain disorder, which slowly destroys memory and cognitive abilities. With RT
